{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T03:49:41Z","timestamp":1782791381109,"version":"3.54.5"},"posted":{"date-parts":[[2024,12,8]]},"group-title":"Neurology","reference-count":59,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2024,12,8]],"date-time":"2024-12-08T00:00:00Z","timestamp":1733616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.medrxiv.org\/about\/FAQ#license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,5,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Early detection of brain amyloidosis (A\u03b2+) is crucial for diagnosing Alzheimer\u2019disease (AD) and optimizing patient management, especially in light of emerging treatments. While plasma biomarkers are promising, their combined diagnostic value through specific ratios remains underexplored. In this study, we assess the diagnostic accuracy of plasma pTau isoform (pTau181 and pTau217) to A\u03b242 ratios in detecting A\u03b2+ status.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This study included 423 participants from the multicenter prospective ALZAN cohort, recruited for cognitive complaints. A\u03b2+ status was determined using cerebrospinal fluid (CSF) biomarkers. The confirmatory cohort comprises 1,176 patient samples from the Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI), with A\u03b2+ status determined by positron emission tomography (PET) imaging. Plasma biomarkers (pTau181, pTau217, A\u03b240, A\u03b242) were measured using immunoassays and mass spectrometry, with specific ratios calculated. In the ALZAN cohort, the impact of confounding factors such as age, renal function, ApoE4 status, body mass index, and the delay between blood collection and processing was also evaluated to assess their influence on biomarker concentrations and diagnostic performance. The primary outcome was the diagnostic performance of plasma biomarkers and their ratios for detecting A\u03b2+ status. Secondary outcomes in the ALZAN cohort included the proportion of patients classified as low, intermediate, or high risk for A\u03b2+ using a two-cutoff approach.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Findings<\/jats:title>\n                  <jats:p>In ALZAN the pTau181\/A\u03b242 ratio matched the diagnostic performance of pTau217 (AUC of 0.911 (0.882-0.940) vs. 0.909 (0.879-0.939), P=0.85). The pTau217\/A\u03b242 ratio demonstrated the highest diagnostic accuracy, with an AUC of 0.927 (0.900-0.954). Both ratios effectively mitigated confounding factors, such as variations in renal function, and were also efficient in identifying A\u03b2+ status in individuals with early cognitive decline. Diagnostic accuracy of ratios vs. individual measurement was confirmed in the ADNI cohort. In ALZAN, using two-cutoff workflows with pTau217\/A\u03b242 instead of pTau217 alone reduced the intermediate-risk zone from \u223c16% to \u223c8%, enhancing stratification for clinical decision-making.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Interpretation<\/jats:title>\n                  <jats:p>The pTau217\/A\u03b242 ratio demonstrated improved diagnostic performance for detecting A\u03b2+ compared to individual biomarkers, potentially reducing diagnostic uncertainty. These findings suggest that plasma biomarker ratios could be useful; however, further validation in independent and diverse clinical settings is necessary before broader clinical implementation.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Funding<\/jats:title>\n                  <jats:p>Fondation Research Alzheimer (ALZAN projet), AXA M\u00e9c\u00e9nat Sant\u00e9 (INTERVAL Project), Fondation pour la Recherche M\u00e9dicale (FRM, team Proteinopathies).<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Research in Context<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Evidence before this study<\/jats:title>\n                    <jats:p>Blood biomarkers of Alzheimer\u2019s disease are receiving increasing attention, as they have great potential for non-invasive detection of the presence of cerebral amyloidosis (A\u03b2+), one of the key elements in the diagnosis of the disease. Among these biomarkers, the phosphorylated isoforms of the tau protein, principally the pTau217 form, show performances that suggest major interest for clinical use. In addition, a number of studies have demonstrated the value of calculating ratios such as A\u03b242\/40 or pTau181\/A\u03b242 in CSF and blood, thereby eliminating the variability associated with pre-analytical or physiological confounding factors, such as renal failure. However, studies directly comparing ratios with individual markers remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Added value of this study<\/jats:title>\n                    <jats:p>In the prospective real-life ALZAN cohort of cognitively impaired participants we show that plasma pTau181\/A\u03b242 and pTau217\/A\u03b242 ratios outperform individual biomarkers for the detection of A\u03b2+ status established from CSF. This result was confirmed for pTau217\/A\u03b242 in the ADNI cohort in which detection of A\u03b2+ status is done with PET. The ratios also show greater resistance to confounding factors such as impaired renal function or delays in sample processing. Finally, by using an approach based on the use of two cutoffs enabling effective population A\u03b2+ risk stratification, the ratios help to reduce the number of inconclusive situations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Implications of all the available evidence<\/jats:title>\n                    <jats:p>Taking previous studies into account, our results strengthen the case for using tau and amyloid ratios, and in particular the plasma pTau217\/A\u03b242 ratio, in the detection of A\u03b2+ status. These ratios not only improve detection accuracy but also help to take confounding factors into account. Ultimately, they could encourage wider use of routine blood tests, making diagnosis earlier, guiding therapeutic decisions while potentially reducing the use of procedures such as lumbar punctures or PET imaging.<\/jats:p>\n                  <\/jats:sec>\n                <\/jats:sec>","DOI":"10.1101\/2024.12.07.24318640","type":"posted-content","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T01:30:16Z","timestamp":1733707816000},"source":"Crossref","is-referenced-by-count":8,"title":["Comparative performance of plasma pTau181\/A\u03b242, pTau217\/A\u03b242 ratios, and individual measurements in detecting brain amyloidosis"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6117-562X","authenticated-orcid":false,"given":"Sylvain","family":"Lehmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Gabelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Duchiron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Germain","family":"Busto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Morchikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8606-6814","authenticated-orcid":false,"given":"Constance","family":"Delaby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Hirtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Mondesert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul","family":"Cristol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevieve","family":"Barnier-Figue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Perrein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Turpinat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Snejana","family":"Jurici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1363-0143","authenticated-orcid":false,"given":"Karim","family":"Bennys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2025060203100740000_2024.12.07.24318640v4.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2013.12.003"},{"key":"2025060203100740000_2024.12.07.24318640v4.2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-026380"},{"key":"2025060203100740000_2024.12.07.24318640v4.3","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13859"},{"issue":"12","key":"2025060203100740000_2024.12.07.24318640v4.4","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/jamaneurol.2024.3770","article-title":"Alzheimer Disease as a Clinical-Biological Construct-An International Working Group Recommendation","volume":"81","year":"2024","journal-title":"JAMA Neurol"},{"key":"2025060203100740000_2024.12.07.24318640v4.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.005"},{"key":"2025060203100740000_2024.12.07.24318640v4.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJ-Moa2212948"},{"key":"2025060203100740000_2024.12.07.24318640v4.7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"2025060203100740000_2024.12.07.24318640v4.8","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-013-1185-7"},{"key":"2025060203100740000_2024.12.07.24318640v4.9","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001991"},{"key":"2025060203100740000_2024.12.07.24318640v4.10","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-024-00755-3"},{"issue":"3","key":"2025060203100740000_2024.12.07.24318640v4.11","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1002\/alz.13609","article-title":"Individuals with Alzheimer\u2019s disease and low tau burden: Characteristics and implications","volume":"20","year":"2024","journal-title":"Alzheimers Dement"},{"key":"2025060203100740000_2024.12.07.24318640v4.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1202753"},{"key":"2025060203100740000_2024.12.07.24318640v4.13","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0079-7"},{"issue":"11","key":"2025060203100740000_2024.12.07.24318640v4.14","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1001\/jamaneurol.2021.3180","article-title":"Head-to-Head Comparison of 8 Plasma Amyloid-beta 42\/40 Assays in Alzheimer Disease","volume":"78","year":"2021","journal-title":"JAMA Neurol"},{"key":"2025060203100740000_2024.12.07.24318640v4.15","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000003246"},{"key":"2025060203100740000_2024.12.07.24318640v4.16","doi-asserted-by":"publisher","DOI":"10.1093\/BRAIN\/AWAC333"},{"key":"2025060203100740000_2024.12.07.24318640v4.17","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2022-330540"},{"issue":"9","key":"2025060203100740000_2024.12.07.24318640v4.18","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/clinchem\/hvad103","article-title":"Head-to-Head Comparison of Two Plasma Phospho-tau Assays in Predicting Conversion of Mild Cognitive Impairment to Dementia","volume":"69","year":"2023","journal-title":"Clin Chem"},{"issue":"7","key":"2025060203100740000_2024.12.07.24318640v4.19","first-page":"P870","article-title":"Mass spectrometry follow-up of t181, s199, s202, t205, and T217 tau phosphorylation in cerebrospinal fluid from patients revealed a specific Alzheimer\u2019s disease pattern","volume":"11","year":"2015","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"2025060203100740000_2024.12.07.24318640v4.20","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-020-00596-4"},{"key":"2025060203100740000_2024.12.07.24318640v4.21","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0781-z"},{"key":"2025060203100740000_2024.12.07.24318640v4.22","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01513-9"},{"key":"2025060203100740000_2024.12.07.24318640v4.23","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2023.5319"},{"issue":"9","key":"2025060203100740000_2024.12.07.24318640v4.24","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1001\/jamaneurol.2024.2619","article-title":"Plasma Phosphorylated Tau 217 and Abeta42\/40 to Predict Early Brain Abeta Accumulation in People Without Cognitive Impairment","volume":"81","year":"2024","journal-title":"JAMA Neurol"},{"key":"2025060203100740000_2024.12.07.24318640v4.25","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2024-333467"},{"key":"2025060203100740000_2024.12.07.24318640v4.26","doi-asserted-by":"crossref","unstructured":"Mielke MM , Dage JL , Frank RD , et al. Performance of plasma phosphorylated tau 181 and 217 in the community. Nat Med 2022.","DOI":"10.1038\/s41591-022-01822-2"},{"key":"2025060203100740000_2024.12.07.24318640v4.27","doi-asserted-by":"publisher","DOI":"10.1038\/s43587-023-00471-5"},{"issue":"8","key":"2025060203100740000_2024.12.07.24318640v4.28","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/alz.12510","article-title":"Characterization of pre-analytical sample handling effects on a panel of Alzheimer\u2019s disease-related blood-based biomarkers: Results from the Standardization of Alzheimer\u2019s Blood Biomarkers (SABB) working group","volume":"18","year":"2022","journal-title":"Alzheimers Dement"},{"issue":"6","key":"2025060203100740000_2024.12.07.24318640v4.29","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/alz.12949","article-title":"Plasma Abeta42\/Abeta40 ratio is independent of renal function","volume":"19","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"2","key":"2025060203100740000_2024.12.07.24318640v4.30","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jamaneurol.2023.4719","article-title":"Effect of Neprilysin Inhibition on Alzheimer Disease Plasma Biomarkers: A Secondary Analysis of a Randomized Clinical Trial","volume":"81","year":"2024","journal-title":"JAMA Neurol"},{"key":"2025060203100740000_2024.12.07.24318640v4.31","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2021-0651"},{"issue":"5","key":"2025060203100740000_2024.12.07.24318640v4.32","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1002\/alz.13764","article-title":"Clinical validation of the PrecivityAD2 blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and Abeta42\/40 ratio to identify presence of brain amyloid","volume":"20","year":"2024","journal-title":"Alzheimers Dement"},{"key":"2025060203100740000_2024.12.07.24318640v4.33","doi-asserted-by":"publisher","DOI":"10.2217\/bmm.12.46"},{"key":"2025060203100740000_2024.12.07.24318640v4.34","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-019-0485-0"},{"issue":"1","key":"2025060203100740000_2024.12.07.24318640v4.35","doi-asserted-by":"crossref","first-page":"e12182","DOI":"10.1002\/dad2.12182","article-title":"Comparing CSF amyloid-beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status","volume":"13","year":"2021","journal-title":"Alzheimers Dement (Amst)"},{"key":"2025060203100740000_2024.12.07.24318640v4.36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2102953\/SUPPL_FILE\/NEJMOA2102953_DISCLOSURES.PDF"},{"key":"2025060203100740000_2024.12.07.24318640v4.37","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12751"},{"key":"2025060203100740000_2024.12.07.24318640v4.38","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-019-00494-6"},{"key":"2025060203100740000_2024.12.07.24318640v4.39","doi-asserted-by":"publisher","DOI":"10.2307\/2531595"},{"key":"2025060203100740000_2024.12.07.24318640v4.40","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12301"},{"key":"2025060203100740000_2024.12.07.24318640v4.41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15436-0"},{"issue":"7","key":"2025060203100740000_2024.12.07.24318640v4.42","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41582-024-00977-5","article-title":"Acceptable performance of blood biomarker tests of amyloid pathology \u2014 recommendations from the Global CEO Initiative on Alzheimer\u2019s Disease","volume":"20","year":"2024","journal-title":"Nature Reviews Neurology"},{"key":"2025060203100740000_2024.12.07.24318640v4.43","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02869-z"},{"issue":"2","key":"2025060203100740000_2024.12.07.24318640v4.44","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3233\/JAD-160865","article-title":"Cerebrospinal Fluid Abeta42\/Abeta40 as a Means to Limiting Tube- and Storage-Dependent Pre-Analytical Variability in Clinical Setting","volume":"57","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"2025060203100740000_2024.12.07.24318640v4.45","first-page":"247","article-title":"Cerebrospinal Fluid Abeta40 Improves the Interpretation of Abeta42 Concentration for Diagnosing Alzheimer\u2019s Disease","volume":"6","year":"2015","journal-title":"Front Neurol"},{"issue":"5 Suppl","key":"2025060203100740000_2024.12.07.24318640v4.46","first-page":"S390","article-title":"Impact of harmonization of collection tubes on Alzheimer\u2019s disease diagnosis","volume":"10","year":"2013","journal-title":"Alzheimers Dement"},{"key":"2025060203100740000_2024.12.07.24318640v4.47","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-020-00696-1"},{"issue":"8","key":"2025060203100740000_2024.12.07.24318640v4.48","first-page":"1484","article-title":"Characterization of pre-analytical sample handling effects on a panel of Alzheimer\u2019s disease-related blood-based biomarkers: Results from the Standardization of Alzheimer\u2019s Blood Biomarkers (SABB) working group","volume":"18","year":"2021","journal-title":"Alzheimers Dement"},{"key":"2025060203100740000_2024.12.07.24318640v4.49","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12897"},{"key":"2025060203100740000_2024.12.07.24318640v4.50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.01.010"},{"issue":"7","key":"2025060203100740000_2024.12.07.24318640v4.51","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2174\/1567205016666190725150836","article-title":"The CSF p-tau181\/Abeta42 Ratio Offers a Good Accuracy \u201cIn Vivo\u201d in the Differential Diagnosis of Alzheimer\u2019s Dementia","volume":"16","year":"2019","journal-title":"Curr Alzheimer Res"},{"issue":"11","key":"2025060203100740000_2024.12.07.24318640v4.52","doi-asserted-by":"crossref","first-page":"e209866","DOI":"10.1212\/WNL.0000000000209866","article-title":"Lumipulse-Measured Cerebrospinal Fluid Biomarkers for the Early Detection of Alzheimer Disease","volume":"103","year":"2024","journal-title":"Neurology"},{"key":"2025060203100740000_2024.12.07.24318640v4.53","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12332"},{"issue":"1","key":"2025060203100740000_2024.12.07.24318640v4.54","doi-asserted-by":"crossref","first-page":"e12375","DOI":"10.1002\/dad2.12375","article-title":"Plasma p-tau181\/Abeta(1-42) ratio predicts Abeta-PET status and correlates with CSF-p-tau181\/Abeta(1-42) and future cognitive decline","volume":"14","year":"2022","journal-title":"Alzheimers Dement (Amst)"},{"issue":"1","key":"2025060203100740000_2024.12.07.24318640v4.55","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3233\/JAD-180321","article-title":"Plasma Abeta42 as a Biomarker of Prodromal Alzheimer\u2019s Disease Progression in Patients with Amnestic Mild Cognitive Impairment: Evidence from the PharmaCog\/E-ADNI Study","volume":"69","year":"2019","journal-title":"J Alzheimers Dis"},{"key":"2025060203100740000_2024.12.07.24318640v4.56","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02074-w"},{"issue":"2","key":"2025060203100740000_2024.12.07.24318640v4.57","first-page":"e14430","article-title":"Influence of medical conditions on the diagnostic accuracy of plasma p-tau217 and p-tau217\/Abeta42","volume":"21","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2025060203100740000_2024.12.07.24318640v4.58","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13195-024-01469-w","article-title":"Combining plasma Abeta and p-tau217 improves detection of brain amyloid in non-demented elderly","volume":"16","year":"2024","journal-title":"Alzheimers Res Ther"},{"key":"2025060203100740000_2024.12.07.24318640v4.59","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14536"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2024.12.07.24318640","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:22:20Z","timestamp":1768508540000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2024.12.07.24318640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,8]]},"references-count":59,"URL":"https:\/\/doi.org\/10.1101\/2024.12.07.24318640","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1016\/j.ebiom.2025.105805","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2024,12,8]]},"subtype":"preprint"}}